13 August 2026 in European Journal of Clinical Investigation
Background: Early oral step‐down has been proposed as a strategy to optimize antimicrobial use in Gram‐negative bloodstream infections (BSIs). Methods: We performed a systematic review and meta‐analysis of full‐text studies published in English and indexed in MEDLINE and EMBASE up to April 2025. Randomized controlled trials (RCTs) and observational studies including patients with Gram‐negative BSIs managed either with oral step‐down within 5 days of IV therapy or with continued IV therapy were eligible. Risk of bias was assessed using the Cochrane Risk of Bias Tool for RCTs and the Newcastle–Ottawa Scale for observational studies. Results: Of 4120 screened records, 13 studies (3 RCTs and 10 cohort studies) including 10,000 patients met the inclusion criteria; 5016 of enrolled patients (52%) switched to oral therapy, mainly to fluoroquinolones (2992, 59.6%). A lower all‐cause mortality was observed in patients receiving oral step‐down (RR: 0.39, 95% CI: 0.16–0.93; p = 0.034). When stratifying studies according to timing of the switch to oral therapy, no significant difference in mortality was observed in studies with a median switch time ≤ 3 days ( p = 0.29). Conversely, studies with a median switch time > 3 days showed a lower mortality rate in the oral step‐down group, approaching statistical significance ( p = 0.051). No significant differences were found between treatment groups in terms of clinical failure ( p = 0.28). Microbiological failure was significantly less frequent among patients receiving oral step‐down therapy (RR = 0.69, 95% CI: 0.49–0.97; p = 0.032), while adverse event rates were comparable ( p = 0.52). However, sensitivity analyses limited to propensity score–adjusted data demostrated no significant differences in mortality ( p = 0.32) or microbiological failure ( p = 0.076). Conclusions: Oral step‐down therapy for Gram‐negative BSIs appears to be a valuable alternative to prolonged IV treatment, potentially reducing IV exposure, complications and healthcare costs without compromising clinical or microbiological outcomes. Trial Registration: PROSPERO registration number: CRD420251056335
1 January 2026 in Case Reports in Infectious Diseases
Background: Granulicatella adiacens (G. adiacens) is a nutritionally variant Streptococcus generally observed in the human mouth microbiota. Although G . adiacens is involved in bacterial endocarditis and bacteremia, bone and joint infections are extremely rare. In the present study, we reported the first known case of hip osteomyelitis related to G. adiacens . Moreover, a commentary on the available evidence was also performed. Case Presentation: A 59‐year‐old male with a former substance use disorder who initially complained of low back pain with a medical history negative for any other comorbidities, albeit absence seizures. After an accurate evaluation, hip osteomyelitis caused by G. adiacens was diagnosed. In our patient, neither bacteremia nor infectious endocarditis was reported, as well as previous oral surgery. The diagnosis of G. adiacens was performed through 16S rRNA gene sequencing. A three‐stage surgery was performed based on surgical debridement and antibiotic‐cemented spacer implant, antibiotic‐cemented spacer renewal, spacer removal, and prosthesis implantation. Throughout the entire period, the patient received antibiotic therapy with doxycycline and cotrimoxazole. At the final follow‐up, the patient was infection‐free, but a poor hip function was reported. Conclusion: G. adiacens is rarely associated with bone osteomyelitis, probably because of the difficulty in culture isolation that might lead to misdiagnosis, especially in cases of polymicrobial infection. In our experience, debridement, prolonged antibiotics, and two‐stage/three‐ stage prosthesis implantation could be considered as a treatment strategy for hip osteomyelitis involving G. a diacens .